https://www.selleckchem.com/products/rsl3.html
To evaluate the effect of delayed start of combination therapy (CT) with dutasteride 0.5mg and tamsulosin 0.4mg on the risk of acute urinary retention or benign prostatic hyperplasia (BPH)-related surgery (AUR/S) in patients with moderate-to-severe lower urinary tract symptoms (LUTS) at risk of disease progression. Using a time-to-event model based on pooled data from 10,238 patients from Phase III/IV dutasteride trials, clinical trial simulations (CTS) were performed to assess the risk of AUR/S up to 48months in moderate-to-severe LUTS/BP
Like
Comment
Share
